NASDAQ OMX (NASDAQ:NDAQ) announced that Recipharm AB (short name: RECI B), a Mid Cap company within the Healthcare sector, today started trading of its shares on the main market of NASDAQ OMX Stockholm. Recipharm is the sixth company to list at NASDAQ OMX’s Nordic main markets in 2014 (NASDAQ OMX Stockholm; Helsinki; Copenhagen and Iceland).

Recipharm is one of Europe’s leading pharmaceutical Contract Development and Manufacturing Organisations (CDMO). Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms including solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, from our facilities across Europe. Headquartered in Sweden, Recipharm employs some 1,500 employees and with a sales turnover in excess of SEK 2.1 bn. The company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain. For more information, visit

Follow RECI B »

Recipharm Listing Ceremony (in English)

Ringing the bell!  Marie Parck, NASDAQ OMX together with Thomas Eldered, CEO and Lars Backsell, Chairman of Recipharm.

Thomas Eldered and Lars Backsell with the listing crystal.

Lars Backsell and Thomas Eldered with one of the machines that is used in the manufacturing at Recipharm.

Group picture of the Recipharm team.